These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
517 related articles for article (PubMed ID: 15853685)
1. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Luno J; Praga M; de Vinuesa SG Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685 [TBL] [Abstract][Full Text] [Related]
2. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials. Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270 [TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
4. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Wolf G; Ritz E Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420 [TBL] [Abstract][Full Text] [Related]
6. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. Krairittichai U; Chaisuvannarat V J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520 [TBL] [Abstract][Full Text] [Related]
7. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855 [TBL] [Abstract][Full Text] [Related]
8. Dual blockade of the renin-angiotensin system in diabetic nephropathy. Wade VL; Gleason BL Ann Pharmacother; 2004; 38(7-8):1278-82. PubMed ID: 15187210 [TBL] [Abstract][Full Text] [Related]
9. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. Ferrari P; Marti HP; Pfister M; Frey FJ J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035 [TBL] [Abstract][Full Text] [Related]
10. Recent changes in the landscape of combination RAS blockade. Epstein BJ; Smith SM; Choksi R Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020 [TBL] [Abstract][Full Text] [Related]
11. Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study. Voskamp PWM; Dekker FW; van Diepen M; Hoogeveen EK; J Am Soc Hypertens; 2017 Oct; 11(10):635-643. PubMed ID: 28802945 [TBL] [Abstract][Full Text] [Related]
12. [Angiotensin II receptor blockers: current status and future prospects]. Corvol P; Plouin PF Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389 [TBL] [Abstract][Full Text] [Related]
13. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis. Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade. Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260 [TBL] [Abstract][Full Text] [Related]
16. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials. Stojiljkovic L; Behnia R Curr Pharm Des; 2007; 13(13):1335-45. PubMed ID: 17506719 [TBL] [Abstract][Full Text] [Related]
17. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy. Dalla Vestra M; Simioni N; Masiero A Int Urol Nephrol; 2009; 41(1):119-26. PubMed ID: 18958580 [TBL] [Abstract][Full Text] [Related]
18. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis. Mori-Takeyama U; Minatoguchi S; Murata I; Fujiwara H; Ozaki Y; Ohno M; Oda H; Ohashi H Clin Exp Nephrol; 2008 Feb; 12(1):33-40. PubMed ID: 18175062 [TBL] [Abstract][Full Text] [Related]
19. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527 [TBL] [Abstract][Full Text] [Related]
20. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition. Alfie J; Aparicio LS; Waisman GD Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]